0
0
Home > Pharmaceuticals >  Clinical Trials Sector Scorecard – Q4 2021 Update – Thematic Research

Clinical Trials Sector Scorecard – Q4 2021 Update – Thematic Research

Most Q4 2021 Activity in ESG Seen in Environmental Initiatives Compared to Social or Governance: In Q4 2021, no major social or governance sustainability activity was detected, however many companies announced new environmental initiatives. For example, AstraZeneca was the only pharma company to have its net zero targets verified by Science Based Targets in line with its new Net Zero Standard. At the 26th United Nations (UN) Climate Change Conference (COP26), the company was also named as one of the first holders of the Terra Carta Seal in recognition of its sustainability efforts, and it was also announced that AstraZeneca was one of 10 pharma companies in the Energize program, a collaboration that supports decarbonization of pharma value chains. Sanofi announced that it had joined the UN’s Race to Zero initiative, which aims to get cities, regions, investors, and top companies to commit to net zero carbon emissions by 2050. Teva issued a sustainability bond linked to both social and environmental targets. GSK announced a significant investment in renewable energy and carbon reduction at manufacturing sites, as well as a new initiative to reduce GHG emissions from its inhalers. Astellas announced that it had begun using biomass-based plastics in blister packages for its products.

Artificial Intelligence, Virtual Care, Cybersecurity, and Real-World Evidence Also Saw Activity in Q4 2021: Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since September 2021. This includes collaborations between Gilead and Amazon Web Services (AWS), Roche and Recursion Pharma, Sanofi and Deloitte, and AstraZeneca with Tempus and with Oncoshot. In virtual care, companies including AbbVie, Sanofi, Eli Lilly, Boehringer Ingelheim, and Biogen posted several jobs relating to virtual trials and initiated trials with virtual components in Q4 2021. Similarly, Sanofi, Johnson & Johnson (J&J), Merck & Co, and Pfizer posted high numbers of jobs relating to cybersecurity in Q4 2021. In real-world evidence (RWE), Merck & Co announced a new collaboration with Syapse to leverage real-world data (RWD) in oncology.

Scope

GlobalData’s Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years.

These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.

The scorecard includes 54 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).

It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.

The methodology section contains information on what data sources were used to generate the thematic scores for each company.

The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.

Understand which key themes should be addressed to drive share price.

Understand which companies are best positioned for success within critical themes and why.

Learn which companies have underinvested in key themes and are most vulnerable to disruption.

Help companies adapt their strategy to anticipate and benefit from these themes as they play out.

Help identify future winners and losers in drug development to inform partnership strategies.

Companies Mentioned

Takeda Pharmaceutical Co Ltd

Merck & Co Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Pfizer Inc

Johnson & Johnson

Boehringer Ingelheim

Parexel International Corp

F. Hoffmann-La Roche Ltd

Novartis AG

GlaxoSmithKline Plc

Bayer AG

Eli Lilly and Co

IQVIA Holdings Inc

AbbVie Inc

Merck KGaA

Novo Nordisk AS

Catalent Inc

Gilead Sciences Inc

Thermo Fisher Scientific Inc

Astellas

Biogen Inc

Cipla Ltd

Lonza Group Ltd

Amgen Inc

Daiichi Sankyo Co Ltd

Vertex Pharmaceuticals Inc

WuXi AppTec Co Ltd

Charles River Laboratories International Inc

CSL Ltd

Reliance Life Sciences Pvt Ltd

Sanofi

Innovent Biologics Inc

Otsuka

Teva Pharmaceutical Industries Ltd

UCB

Dr. Reddy's Laboratories Ltd

Regeneron Pharmaceuticals Inc

Samsung Bioepis Co Ltd

Sun Pharmaceutical Industries Ltd

Biocad

Cadila Pharmaceuticals Ltd

Celltrion Inc

Coherus BioSciences Inc

CSPC Pharmaceutical Group Ltd

Generium

Intas Pharmaceuticals Ltd

Lupin Ltd

Perrigo Co Plc

Pharmaceutical Product Development LLC

Seagen Inc

Shanghai Henlius Biotech Inc

Viatris Inc

Zydus Cadila

Table of Contents

Executive Summary

Introduction

• Pharma Theme Map

Clinical Trials Scorecard: Key Q4 2021 Updates

• Company Screen

• Thematic Screen

• Valuation Screen

Our Thematic Research Methodology

• How Our Pharma Scores Are Generated

Related Reports

About the Authors

About GlobalData

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports